Generex Biotechnology Corp., of Worcester, Mass., reported early results from a Phase II study of its AE37 vaccine in patients with HER2 low-expressing and triple-negative breast cancer, which showed an overall reduction of 42 percent in the risk of relapse in all patients in the study who received the vaccine, and a 66 percent reduction in the risk of relapse for patients with low expression of the HER2 oncoprotein who were classified as having triple-negative breast cancer.
Suite: 1100 | Atlanta, Georgia 30346, USA
In the U.S. and Canada: 1-800-477-6307
Outside the U.S.: 1-770-810-3144
In the U.S. and Canada: 1-800-336-4474
Outside the U.S.: 1-215-386-0100
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter